Serina Therapeutics Inc - Asset Resilience Ratio
Serina Therapeutics Inc (SER) has an Asset Resilience Ratio of 83.31% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Serina Therapeutics Inc (SER) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Serina Therapeutics Inc's Asset Resilience Ratio has changed over time. See SER book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Serina Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SER market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $8.62 Million | 69.44% |
| Short-term Investments | $1.72 Million | 13.86% |
| Total Liquid Assets | $10.34 Million | 83.31% |
Asset Resilience Insights
- Very High Liquidity: Serina Therapeutics Inc maintains exceptional liquid asset reserves at 83.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Serina Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Serina Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT |
Biotechnology | 63.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bio-Thera Solutions Ltd
SHG:688177 |
Biotechnology | 4.09% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Gubra A/S
CO:GUBRA |
Biotechnology | 79.61% |
Annual Asset Resilience Ratio for Serina Therapeutics Inc (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Serina Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 54.61% | $3.67 Million | $6.72 Million | +50.76pp |
| 2023-12-31 | 3.85% | $345.00K | $8.97 Million | -16.05pp |
| 2022-12-31 | 19.90% | $645.00K | $3.24 Million | -11.69pp |
| 2021-12-31 | 31.59% | $996.45K | $3.15 Million | -- |
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more